Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, ...

Below is a summary assembled by the Research & Innovation Office (RIO). Please see the Tang Prize website for complete information. The Tang Prize comprises four categories, namely Sustainable ...

DURHAM, N.C. & CARLSBAD, Calif.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing ...

Safety and efficacy of two candidates are currently being assessed in investigator-initiated clinical trials. BRC is planning to commence enrollment for Phase 2 and 3 trials by mid 2026. MONTEREY, ...

In process monitoring is important for optimizing cell culture conditions such as nutrient concentrations, cell viability, and metabolite production as well as product quality attributes such as ...

AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning ...

Solubility is fundamental in successfully developing all classes of therapeutic biopolymers. Contact with stressors related to mechanical stirring or changes in buffer conditions may cause ...

Program further validates Willow's BioOxi™ technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ ...

The biopharmaceutical industry faces strict regulations worldwide, making it essential to meet international standards before any new therapy can enter the market. Staying informed about the current ...

SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have ...

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...

MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...